Flow Neuroscience has secured FDA approval for FL-100, the first at-home brain stimulation device for major depressive disorder.

Agreement has been reached on the reform of EU pharma legislation, but industry thinks it does not go far enough to restore the bloc’s global status.

Umoja Biopharma, one of the most well-capitalized developers of in vivo CAR-T therapy, is delaying its first clinical readout from its China-based first trial. The startup told Endpoints News that it now expects to share …

Share price falls of 90% are mercifully rare in biopharma — but as Rezolute discovered Thursday, not entirely unknown. The wholesale failure of the Phase 3 trial of the company’s only drug, which is intended to …

Rhythm Pharmaceuticals unveiled initial data from a mid-stage study of its MC4R agonist in patients with a rare disease that causes excessive hunger. The biotech’s Imcivree led to BMI reductions in six out of eight …

Swiss biotech AC Immune, researching immunological treatments for neurodegenerative disorders, reported interim Parkinson’s disease data Thursday, suggesting it may slow the progression of the condition. But the interpretation of its clinical endpoints remains unclear, particularly …

Plus, news about AstraZeneca, Moderna, Nanexa, Phare Bio, Basilea Pharmaceutica, Immunovant and Aukera Therapeutics: 💊 Corbus Pharmaceuticals reports obesity pill data: Nine patients with obesity given a cannabinoid type-1 (CB1) inverse agonist, dubbed CRB …

Eli Lilly has ramped up the competition in weight-loss therapies by reporting the first pivotal data with its triple therapy retatrutide.

As the health tech market slowly picks back up, investors are thinking outside the box with ways to get their money back. After a roller coaster of uncertainty in the markets earlier this year, most …